Seal Rock Therapeutics’ SRT-015 to treat alcoholic hepatitis: Likelihood of approval

In addition to indication benchmarks based on 18 years of historical drug development data, GlobalData also tracks the likelihood of phase change and approval scores for specific drugs. The attributes of the drug, the company, and its clinical trials play an important role in drug-specific PTSR and likelihood of approval.

SRT-015 Overview

SRT-015 is being developed for the treatment of non-alcoholic steatohepatitis (NASH), alcoholic hepatitis and acute episode of chronic liver failure (ACLF). It is administered by oral and intravenous routes. The drug candidate works by targeting apoptosis signal-regulating kinase 1 (ASK1/MAP3K5 (mitogen-activated protein kinase kinase kinase 5)).

Seal Rock Therapy Overview

Seal Rock Therapeutics (Seal Rock) discovers and develops new treatments for liver disease. The company’s lead product candidate, SRT-015, is a liver-selective ASK1 inhibitor targeting non-alcoholic steatohepatitis (NASH), non-alcoholic fatty liver disease (NAFLD) and fatty liver disease. It is also evaluating small molecule inhibitors of apoptosis signal-regulated kinase (ASK1) inhibitors, immunological, cardiac targeting and neurodegenerative disease indications. Seal Rock is headquartered in Seattle, Washington, USA.

For a comprehensive view of SRT-015 drug-specific PTSR and LoA scores, purchase the report here.

Desde

The gold standard in business intelligence.

GlobalData’s unparalleled proprietary data combines expertise with cutting-edge technology, allowing you to decipher what’s happening in the market. You can make smarter decisions and gain a future-proof advantage over your competitors.

better understand the situation